| S-glutathionylated PFKFB3 | | homo-2-mer | 3-461 | 100.0 | 2×ADP; 4×MLA; 2×ACY; 2×GSH; 2×F6P; |
|
| PFKFB3 in complex with ADP and PEP | | homo-2-mer | 3-461 | 100.0 | 2×F6P; 2×ADP; 2×PEP; |
|
| Crystal structure of PFKFB3 in complex with ADP and Fructose-2,6-bisphosphate | | homo-2-mer | 3-461 | 100.0 | 2×FDP; 2×F6P; 2×ADP; 2×PHS; |
|
| PFKFB3 trapped in a phospho-enzyme intermediate state | | homo-2-mer | 4-460 | 100.0 | 2×FDP; 2×PHS; 2×ADP; 2×F6P; |
|
| Human PFKFB3 in complex with an indole inhibitor 6 | | homo-2-mer | 2-446 | 100.0 | 2×PHS; 4×PO4; 2×F6P; 2×8V1; |
|
| Human PFKFB3 in complex with an indole inhibitor 2 | | homo-2-mer | 2-446 | 100.0 | 2×PHS; 2×PO4; 2×F6P; 2×S6L; |
|
| human PFKFB3 in complex with a pyrrolopyrimidone compound | | homo-2-mer | 2-446 | 100.0 | 2×PO4; 2×PHS; 2×F6P; 2×BKI; |
|
| human PFKFB3 in complex with a pyrrolopyrimidone compound | | homo-2-mer | 2-446 | 100.0 | 2×PHS; 2×PO4; 2×F6P; 2×BKS; |
|
| human PFKFB3 in complex with a pyrrolopyrimidone compound | | homo-2-mer | 2-446 | 100.0 | 2×PHS; 2×PO4; 2×F6P; 2×BKE; |
|
| PFKFB3 in complex with PPi | | homo-2-mer | 4-447 | 100.0 | 6×POP; 4×SRT; 4×EDO; |
|
| human PFKFB3 in complex with a pyrrolopyrimidone compound | | homo-2-mer | 2-445 | 100.0 | 4×PO4; 2×PHS; 2×F6P; 2×BKV; |
|
| Human PFKFB3 in complex with an indole inhibitor 5 | | homo-2-mer | 3-446 | 100.0 | 2×PHS; 2×F6P; 2×PO4; 2×MJP; |
|
| Human PFKFB3 in complex with an indole inhibitor 4 | | homo-2-mer | 2-445 | 100.0 | 2×PHS; 2×PO4; 2×F6P; 2×87T; |
|
| Human PFKFB3 in complex with an indole inhibitor 3 | | homo-2-mer | 2-445 | 100.0 | 2×PHS; 2×PO4; 2×F6P; 2×FD9; |
|
| Human PFKFB3 in complex with an indole inhibitor 1 | | homo-2-mer | 3-446 | 100.0 | 6×PO4; 2×8R2; 2×FDP; |
|
| A pseudo substrate complex of 6-phosphofructo-2-kinase of PFKFB | | homo-2-mer | 4-446 | 100.0 | 4×F6P; 2×MG; 2×ACP; |
|
| HUMAN PFKFB3 IN COMPLEX WITH KAN0438241 | | homo-2-mer | 4-445 | 100.0 | 2×DMS; 2×F6P; 2×BWW; 2×ADP; |
|
| PFKFB3 in complex with Aluminum Tetrafluoride | | homo-2-mer | 4-440 | 100.0 | 2×ALF; 2×ADP; 2×PEP; 2×CL; |
|
| Crystal structure of the human inducible form 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase | | monomer | 3-517 | 100.0 | 1×F6P; 1×EDT; 1×ADP; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 2 | | monomer | 2-447 | 100.0 | 1×GV5; 1×POP; 1×F6P; 1×FLC; 1×DMS; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 5 | | monomer | 4-447 | 100 | 1×H9Z; 1×POP; 1×FLC; 1×F6P; 1×DMS; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 3 | | monomer | 4-447 | 100.0 | 1×GV8; 1×F6P; 1×PO4; 1×FLC; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 1 | | monomer | 4-447 | 100.0 | 1×GV2; 1×POP; 1×FLC; 1×F6P; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 7 | | monomer | 4-447 | 100 | 1×PO4; 1×FLC; 1×HAW; 1×F6P; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 6 | | monomer | 4-447 | 100 | 1×HAT; 1×POP; 1×FLC; 1×F6P; 1×BME; 1×PO4; |
|
| Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 4 | | monomer | 4-446 | 100 | 1×HAK; 1×POP; 1×FLC; 1×F6P; 1×DMS; |
|